ESR1 and breast cancer: VERITAC-2 (ClinicalTrials.gov identifier: NCT05654623) is a phase 3 study that compares the efficacy and safety of vepdegestrant with fulvestrant in patients with ER+/HER2− advanced breast cancer after prior combination endocrine therapy and CDK4/6 inhibitor therapy [124].